BLUE BELL, PA March 10, 2003 - InKine Pharmaceutical Company, Inc. (Nasdaq: INKP) today announced that Leonard S. Jacob, M.D., Ph.D., Chairman and CEO of InKine, will be a panelist at The Wall Street Transcript's Specialty Pharmaceutical Investment Conference on Thursday, March 20, 2003 at 9:30 AM EST. Dr. Jacob will be part of a distinguished panel to discuss the future of the specialty pharmaceutical industry.
Dr. Jacob commented, "We are delighted to participate in such a conference as we continue to show marked improvement in our own specialty pharmaceutical operations due to the success of the re-launch of Visicol. Recent audited IMS prescription data indicates that once again Visicol, InKine's lead product, achieved an all time monthly high of over 26,000 prescriptions for January 2003. This represents a 9% penetration of the ethical market for purgative products."
About InKine Pharmaceutical
InKine Pharmaceutical Company, Inc. is a publicly traded biopharmaceutical company focused on the diagnosis and treatment of cancer and autoimmune diseases. The Company's development strategy is to acquire late-stage drug candidates with short time lines to commercialization. The Company's first product, Visicol® is the first and only tablet purgative preparation indicated for bowel cleansing prior to colonoscopy. InKine's second product, IBStat®, is a novel oral hysocyamine spray for the treatment of Irritable Bowel Syndrome (IBS) and spasm of the colon. Additionally, the Company has other development programs such as Colirest, which is in clinical trials for the treatment of Crohn's disease and completed Phase II trials for the treatment of ulcerative colitis. For further information, please visit InKine on their web site http://www.inkine.com.
In addition to historical facts or statement of current condition, this press release may contain forward-looking statements. Forward-looking statements provide InKine's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings projections, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. InKine's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties such as those set forth in its reports on Form 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, InKine does not intend (and it is not obligated) to update publicly any forward-looking statements. This discussion is permitted by the Private Securities Litigation Reform Act of 1995.